PRECISION BIOSCIENCES INC (DTIL)

US74019P2074 - Common Stock

5.7  +1.2 (+26.67%)

After market: 5.68 -0.02 (-0.35%)

Fundamental Rating

2

Overall DTIL gets a fundamental rating of 2 out of 10. We evaluated DTIL against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of DTIL have multiple concerns. DTIL is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

DTIL had negative earnings in the past year.
In the past year DTIL has reported a negative cash flow from operations.
DTIL had negative earnings in each of the past 5 years.
DTIL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DTIL has a Return On Assets of 5.63%. This is amongst the best in the industry. DTIL outperforms 95.14% of its industry peers.
With an excellent Return On Equity value of 13.29%, DTIL belongs to the best of the industry, outperforming 95.86% of the companies in the same industry.
Industry RankSector Rank
ROA 5.63%
ROE 13.29%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-42.36%
ROE(3y)-181.13%
ROE(5y)-171.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 11.48%, DTIL belongs to the top of the industry, outperforming 95.32% of the companies in the same industry.
DTIL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 11.48%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

DTIL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DTIL has been increased compared to 1 year ago.
The number of shares outstanding for DTIL has been increased compared to 5 years ago.
Compared to 1 year ago, DTIL has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.10, we must say that DTIL is in the distress zone and has some risk of bankruptcy.
DTIL has a Altman-Z score (-3.10) which is in line with its industry peers.
DTIL has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.34, DTIL is doing worse than 71.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -3.1
ROIC/WACCN/A
WACC11.08%

2.3 Liquidity

A Current Ratio of 9.22 indicates that DTIL has no problem at all paying its short term obligations.
DTIL has a Current ratio of 9.22. This is in the better half of the industry: DTIL outperforms 78.20% of its industry peers.
DTIL has a Quick Ratio of 9.22. This indicates that DTIL is financially healthy and has no problem in meeting its short term obligations.
DTIL has a better Quick ratio (9.22) than 78.38% of its industry peers.
Industry RankSector Rank
Current Ratio 9.22
Quick Ratio 9.22

More info and screens

4

3. Growth

3.1 Past

DTIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.95%, which is quite impressive.
Looking at the last year, DTIL shows a very strong growth in Revenue. The Revenue has grown by 43.62%.
Measured over the past years, DTIL shows a very strong growth in Revenue. The Revenue has been growing by 34.96% on average per year.
EPS 1Y (TTM)89.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
Revenue 1Y (TTM)43.62%
Revenue growth 3Y26.13%
Revenue growth 5Y34.96%
Sales Q2Q%-95.61%

3.2 Future

DTIL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.17% yearly.
DTIL is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.80% yearly.
EPS Next Y111.65%
EPS Next 2Y25.28%
EPS Next 3Y19.58%
EPS Next 5Y11.17%
Revenue Next Year34.68%
Revenue Next 2Y-38.72%
Revenue Next 3Y-15.89%
Revenue Next 5Y-7.8%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DTIL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DTIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DTIL's earnings are expected to grow with 19.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.28%
EPS Next 3Y19.58%

More info and screens

0

5. Dividend

5.1 Amount

DTIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRECISION BIOSCIENCES INC

NASDAQ:DTIL (1/10/2025, 7:21:49 PM)

After market: 5.68 -0.02 (-0.35%)

5.7

+1.2 (+26.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)N/A N/A
Inst Owners39.31%
Inst Owner Change0%
Ins Owners3.03%
Ins Owner Change0.14%
Market Cap43.72M
Analysts83.64
Price Target34.27 (501.23%)
Short Float %4.17%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)194.74%
Min EPS beat(2)-14.74%
Max EPS beat(2)404.22%
EPS beat(4)2
Avg EPS beat(4)94.28%
Min EPS beat(4)-94.4%
Max EPS beat(4)404.22%
EPS beat(8)5
Avg EPS beat(8)59.01%
EPS beat(12)7
Avg EPS beat(12)40.82%
EPS beat(16)10
Avg EPS beat(16)29.76%
Revenue beat(2)1
Avg Revenue beat(2)180.64%
Min Revenue beat(2)-91.12%
Max Revenue beat(2)452.4%
Revenue beat(4)2
Avg Revenue beat(4)125.73%
Min Revenue beat(4)-91.12%
Max Revenue beat(4)452.4%
Revenue beat(8)6
Avg Revenue beat(8)106.74%
Revenue beat(12)7
Avg Revenue beat(12)64.37%
Revenue beat(16)10
Avg Revenue beat(16)93.85%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.36%
EPS NY rev (1m)0%
EPS NY rev (3m)3036%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-6.91
Fwd EYN/A
FCF(TTM)-6.3
FCFYN/A
OCF(TTM)-6.28
OCFYN/A
SpS9.79
BVpS8.46
TBVpS8.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.63%
ROE 13.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 11.48%
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-42.36%
ROE(3y)-181.13%
ROE(5y)-171.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.09%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.22
Quick Ratio 9.22
Altman-Z -3.1
F-Score5
WACC11.08%
ROIC/WACCN/A
Cap/Depr(3y)46.86%
Cap/Depr(5y)132.36%
Cap/Sales(3y)7.64%
Cap/Sales(5y)30.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.14%
EPS Next Y111.65%
EPS Next 2Y25.28%
EPS Next 3Y19.58%
EPS Next 5Y11.17%
Revenue 1Y (TTM)43.62%
Revenue growth 3Y26.13%
Revenue growth 5Y34.96%
Sales Q2Q%-95.61%
Revenue Next Year34.68%
Revenue Next 2Y-38.72%
Revenue Next 3Y-15.89%
Revenue Next 5Y-7.8%
EBIT growth 1Y60.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.56%
EBIT Next 3Y15.99%
EBIT Next 5Y10.49%
FCF growth 1Y6.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.25%
OCF growth 3YN/A
OCF growth 5YN/A